Inaedis is a biopharmaceutical technology company developing a scalable, cGMP-compatible platform that removes the fundamental formulation, manufacturing, and delivery constraints limiting today’s biologics. Originating from research at Princeton University, Inaedis was founded to address a critical industry problem: most biologics remain expensive, fragile, cold-chain dependent, and tied to invasive administration routes.
Biologics now account for nearly half of prescription drug spending, yet their impact is constrained by instability, complex logistics, and IV-centric delivery. Conventional formulation and drying technologies—lyophilization and spray drying—are energy intensive, poorly scalable, and impose thermal and mechanical stresses that damage sensitive biologics. These limitations drive high costs, manufacturing risk, cold-chain failures, and limited patient access.
Inaedis was created to change this equation.
Technology
Inaedis’ proprietary Room Temperature Aerosol Dehydration (RTAD) platform enables rapid, continuous, no-added-heat dehydration of liquid biologics into stable powders or particle-based suspensions. RTAD uses ultra-fine droplet formation and millisecond-scale drying at room temperature, reducing dehydration-induced stress by orders of magnitude compared with conventional methods.
The result is a formulation and manufacturing platform that:
- Preserves biological activity and minimizes aggregation
- Enables room-temperature-stable drug products
- Scales continuously with consistent process parameters
- Integrates with existing cGMP spray drying infrastructure through retrofit, rather than greenfield build
RTAD is compatible with antibodies, proteins, viral vectors, lipid nanoparticles, and other fragile biologics that fail under traditional drying approaches.
What RTAD Enables
From a single core platform, Inaedis unlocks multiple high-value drug product classes:
Ultra-high concentration biologics
RTAD enables suspension-based formulations exceeding 500 mg/mL with low viscosity, allowing subcutaneous injection through standard needles and autoinjectors—eliminating long IV infusions and enabling at-home administration.
Cold-chain-independent biologics and vaccines
By converting biologics into stable dry particles, RTAD reduces reliance on refrigerated and ultracold storage, mitigating the billions lost annually to cold-chain failures and enabling global distribution and stockpiling.
Inhaled and intranasal biologics and vaccines
RTAD produces particles with tunable sizes across the inhalable and nasal range, enabling pulmonary and intranasal delivery of biologics that are impractical to deliver by injection.
Next-generation delivery formats
The platform supports microneedle patches, reconstitutable injectables, and other patient-centric formats that improve adherence, safety, and clinical outcomes.
Why It Matters
RTAD is not a single-product solution—it is a platform advantage across the biopharmaceutical value chain.
- Patient impact: Shorter administration times, non-invasive delivery, at-home dosing, and improved safety profiles
- Manufacturing advantage: Continuous processing, predictable scale-up, and 5–10× capacity gains from existing assets
- Capital efficiency: Retrofit instead of $50M+ greenfield investments
- Supply-chain resilience: Shelf-stable products enable global access, defense readiness, and rapid outbreak response
- Lifecycle value: Novel formulation IP can extend product lifetimes and delay biosimilar competition
Validation and Traction
Inaedis’ technology has been validated across multiple biologic modalities, demonstrating preserved potency, dramatically reduced aggregation, and consistent scale-up to pilot throughput. The platform is protected by an exclusive IP portfolio licensed from Princeton University and supported by peer-reviewed publications.
Inaedis has received non-dilutive funding from NSF, NIH, DoD, and state innovation programs and has completed the Merck Digital Sciences Studio. Ongoing collaborations with pharmaceutical companies, CDMOs, and public-sector stakeholders validate strong demand for scalable, patient-centric biologic formulation technologies.
Our Mission
Inaedis exists to remove the structural barriers that limit biologic drugs today. By enabling ultra-gentle, scalable, room-temperature drug product formulation that unlocks thermal stability and self-administration of biologics and vaccines, we help innovators deliver more effective, accessible, and resilient biologic medicines—at lower cost and on a global scale.